< All Topics

Development of Electrochemical Immunosensors towards Point-of-care Cancer Diagnostics: Clinically Relevant Studies


Electroanalysis. 2016: doi.org/10.1002/elan.201600248



Rawiwan Laocharoensuk

Quansys Products Used:

Human Cytokine (4-Plex)


Development of electrochemical biosensors towards cancer biomarker detection has been in the spot light for several decades. Electrochemical detection holds great promise for clinical applications because it offers several advantages including sensitive, fast, simple and low‐cost. In addition, multiplexing capability for simultaneous detection of multiple biomarkers is feasible. Unfortunately, transition of biosensors from laboratories to the market is challenging. This review intends to summarize recent advances in the development of electrochemical immunosensors for the next generation cancer diagnostic devices. Clinically relevant details of cancer biomarkers such as threshold value and their diagnosis/prognosis application will be given in conjunction with the electrochemical detection platforms that have been validated using clinical samples. Finally, the critical aspects that require great attention in order to fulfill the criteria of biomedical diagnostics will be covered.

Previous Elevated ccl19 after completion of therapy for acute lyme disease identifies patients at risk for development of post-treatment lyme disease syndrome who will benefit from further antibiotic therapy